Clik here to view.
Mubadala, CBC Group ink $680M deal for UCB’s neurology and allergy portfolio...
Belgian pharma UCB is selling parts of its China business to Mubadala and CBC Group for $680 million. In addition to taking over UCB’s “mature product portfolio” in China, the Abu Dhabi sovereign...
View ArticleClik here to view.
Major Galapagos investor says it will push board on company's 'performance'...
One of Galapagos’ biggest shareholders is taking a more active role in pushing the company’s turnaround. Biotech investment firm EcoR1 Capital, which owns 9.9% of the company’s shares, said in a Friday...
View ArticleMpox vaccine collab; $11M oncology seed; Gates backs RSV vaccine; Kyowa Kirin...
Houston biotech closes $11.4 million seed round: Diakonos Oncology said the money will fund operations into late 2025. A Phase 2 trial testing its dendritic cell vaccine program in glioblastoma is...
View ArticleClik here to view.
Once one of immuno-oncology's next great hopes, CD47 faces final shots on goal
Earlier this summer, a small biotech company’s readout in what was once one of cancer’s most intriguing approaches did little to settle the controversy and questions surrounding it. The CD47 pathway,...
View ArticleRegeneron wins EU approval for lymphoma bispecific following FDA rejection
EU regulatory authorities granted conditional approval to Regeneron’s bispecific antibody odronextamab for two forms of lymphoma. It’s Regeneron’s first bispecific antibody approval in the world after...
View ArticleAnother major PBM will cut AbbVie's Humira from its largest commercial...
Cigna’s pharmacy benefit manager Express Scripts said it will remove Humira from its largest commercial drug formularies in 2025 to make way for its biosimilars. The move will make Express Scripts the...
View ArticleNovartis to sell molecular imaging business to Siemens Healthineers
Novartis is selling off its molecular imaging business for positron emission tomography (PET) scans to Siemens Healthineers for an undisclosed amount, both companies confirmed to Endpoints News on...
View ArticleFederal agency opposes J&J's new 340B discount model, promises to take...
The federal government is challenging Johnson & Johnson’s plan to change how some hospitals receive drug price discounts under the 340B program. Last week, J&J announced that beginning Oct. 15,...
View ArticleClik here to view.
Swiss biotech's inhibitor of cancer driver shows promise in rare bleeding...
Vaderis Therapeutics announced Tuesday morning that its lead drug candidate, an AKT inhibitor, helped reduce nosebleeds in people with hereditary hemorrhagic telangiectasia, a genetic disorder in which...
View ArticlePfizer unveils direct-to-consumer push for Covid, flu and migraine treatments
Pfizer is expanding its direct-to-patient sales offerings. On Tuesday, the New York pharma launched a new website, called PfizerForAll, that connects patients to clinicians who can prescribe its...
View ArticleOculis closes Phase 3 eye drop trial due to 'administrative error' from third...
A Phase 3 trial for Oculis’ lead eye drop candidate will be shut down due to an administrative error, the company reported in its second-quarter financial filing. The OPTIMIZE-2 trial was investigating...
View ArticleRA Capital and Forbion set up new autoimmune biotech with bispecific from...
Another autoimmune biotech emerged on Tuesday morning with a $100 million Series A. Navigator Medicines launched with a license to a Phase 1 bispecific antibody and a pipeline of other assets from...
View ArticleClik here to view.
Elektrofi, a startup that helps drugmakers formulate biologics for easier...
Biologics startup Elektrofi is raising an approximately $112 million Series C, CEO and co-founder Chase Coffman confirmed to Endpoints News. Chase Coffman The Boston-based startup works with pharma and...
View ArticleIllumina wins FDA approval for test to identify treatable cancers
The FDA has approved DNA sequencing giant Illumina’s cancer test that checks more than 500 genes in a tumor to potentially match patients with targeted therapies from Bayer or Eli Lilly. Illumina has...
View ArticleInvivyd says new Phase 3 data on Covid antibody support prophylactic use
Invivyd’s monoclonal antibody can cut the risk of contracting Covid-19 in both healthy and immunocompromised people, according to the latest exploratory analysis from a Phase 3 trial. The biotech’s...
View ArticleClik here to view.
Former Regenxbio leaders take rare disease gene therapies to startup with $15M
Two Regenxbio gene therapies are getting a second chance at newly-seeded startup Tern Therapeutics, which launched from stealth Tuesday with $15 million. In November, Regenxbio announced it was laying...
View ArticleRedalpine closes $200M fund; A base editing pact in China; Merck starts...
Plus, a Phase 3 fail from a small public company: Redalpine’s $200M fund: The nearly two-decade-old VC firm closed its sixth early-stage fund, dubbed RAC VII. The Zurich-based firm has invested in...
View ArticleClik here to view.
Once-promising cancer drugs appear to protect mice from Alzheimer’s
Drugs designed to help the immune system fight cancer might also stave off dementia, according to a study in mice. Researchers at Stanford University discovered a new role for the metabolic enzyme IDO1...
View ArticleDuality Biologics, an ADC partner of BeiGene and BioNTech, files for Hong...
Clinical-stage antibody-drug conjugate startup Duality Biologics has filed for an initial public offering in Hong Kong, where there have been only a handful of biotech listing debuts in recent...
View ArticleAstraZeneca pours $135M into boosting biologics capacity in Sweden
AstraZeneca is spending $135 million to expand a biologics facility in Sweden due to an increase in demand for its pre-filled syringe drug products, a company spokesperson told Endpoints News. The...
View Article